<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222545</url>
  </required_header>
  <id_info>
    <org_study_id>OMS721-TMA-001</org_study_id>
    <secondary_id>2014-001032-11</secondary_id>
    <nct_id>NCT02222545</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies</brief_title>
  <official_title>A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeros Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK),&#xD;
      pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic&#xD;
      microangiopathies (TMA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, uncontrolled, 3-stage, ascending-dose-escalation study in patients with 1&#xD;
      of 3 forms of TMA: atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenia&#xD;
      (TTP), and hematopoietic stem cell transplant - associated TMA (HSCT-associated TMA). In&#xD;
      Stage 1 of the study, OMS721 was administered to 3 cohorts, with dose escalation by cohort to&#xD;
      identify the optimal dosing regimen. In Stage 2, the dose selected in the first stage was&#xD;
      administered to expanded cohorts of patients with distinct etiologies (aHUS alone in 1 cohort&#xD;
      and TTP or HSCT-TMA in the other cohort). Patients completing Stage 2 were eligible for&#xD;
      continued treatment in Stage 3 if they tolerated OMS721 treatment and derived clinical&#xD;
      benefit. Enrollment in the study has been completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2014</start_date>
  <completion_date type="Actual">August 11, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>4 to 24 weeks</time_frame>
    <description>Incidence of Adverse Events, vital signs, ECG, and clinical laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the response rate to OMS721 in patients with HSCT-TMA</measure>
    <time_frame>4 to 24 weeks</time_frame>
    <description>Improvement in TMA laboratory markers of platelet count and lactate dehydrogenase (LDH) and improvement in clinical status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA treated with OMS721: 100-day survival</measure>
    <time_frame>Study Day 1 to 100 days later</time_frame>
    <description>Vital status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA treated with OMS721: Overall survival</measure>
    <time_frame>Study Day 1 to up to 2 years following first dose of OMS721</time_frame>
    <description>Vital status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA treated with OMS721: Duration of response</measure>
    <time_frame>Study Day 1 to up to 2 years following first dose of OMS721</time_frame>
    <description>Number of days from the first response date to the first relapse date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA treated with OMS721: Freedom from platelet transfusion</measure>
    <time_frame>Study Day -14 to 4 weeks following the last platelet transfusion</time_frame>
    <description>Absence of platelet transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA treated with OMS721: Freedom from red blood cell (RBC) transfusion</measure>
    <time_frame>Study Day -14 to 4 weeks following the last RBC transfusion</time_frame>
    <description>Absence of RBC transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA treated with OMS721: Change from baseline in platelet count, LDH, haptoglobin, hemoglobin (Hgb), creatinine</measure>
    <time_frame>Study Day 1 to up to 2 years following the first dose of OMS721</time_frame>
    <description>Platelet count, LDH, haptoglobin, Hgb, creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA, aHUS, and TTP: Pharmacokinetics (PK) of multiple-dose administration of OMS721</measure>
    <time_frame>Pre-dose and up to 204 days post-dose</time_frame>
    <description>PK parameters including maximum concentration, time to maximum concentration, elimination half-life, area under time-concentration curve, clearance, and volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA, aHUS, and TTP: Pharmacodynamics (PD) of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>Pre-dose and up to 204 days post-dose</time_frame>
    <description>PD measure in inhibition of ex vivo lectin pathway activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the following in patients with HSCT-TMA, aHUS, and TTP: Immunogenicity of multiple-dose administration of OMS721 in subjects with TMA</measure>
    <time_frame>Pre-dose and up to 204 days post-dose</time_frame>
    <description>Presence of ADA response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Thrombotic Microangiopathies</condition>
  <arm_group>
    <arm_group_label>OMS721 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 at a low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMS721 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 at a medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMS721 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of OMS721 at a high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OMS721</intervention_name>
    <arm_group_label>OMS721 high dose</arm_group_label>
    <arm_group_label>OMS721 low dose</arm_group_label>
    <arm_group_label>OMS721 medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are at least age 18 at screening (Visit 1)&#xD;
&#xD;
          2. Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP&#xD;
&#xD;
          3. No clinically apparent alternative explanation for thrombocytopenia and anemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had eculizumab therapy within three months prior to screening&#xD;
&#xD;
          2. Have STEC-HUS&#xD;
&#xD;
          3. Have a positive direct Coombs test&#xD;
&#xD;
          4. Have an active systemic bacterial or fungal infection requiring antimicrobial therapy&#xD;
             (prophylactic antimicrobial therapy administered as standard of care is allowed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>PokFuLam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Pathum Thani</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omeros Investigational Site</name>
      <address>
        <city>Pathumwan</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMA, aHUS, HSCT-associated TMA, TTP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

